🔎 Trials Near Me

Akèy › Leksemi biphenotipik egi › Georgia

Etid klinik pou Leksemi biphenotipik egi nan Georgia

9 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan Georgia.

Vil nan Georgia

Tèks ofisyèl etid la (Anglè)

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • Emory University, Atlanta
Ap rekriteFaz 1
Laj 12 a 78 · Tout sèks · Mizajou Sep 29, 2026 · NCT03802695

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Emory Winship Cancer Institute, Atlanta
Ap rekriteFaz 1/2
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
  • Augusta University Medical Center, Augusta
  • Atrium Health Navicent, Macon
  • ak 1 plis
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
  • Memorial Health University Medical Center, Savannah
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Children's Healthcare of Atlanta, Atlanta
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06177067

Venetoclax Basket Trial for High Risk Hematologic Malignancies

  • Children's Healthcare of Atlanta at Arthur M. Blank Hospital, Atlanta
Ap rekriteFaz 1
Laj 1 a 40 · Tout sèks · Mizajou Mar 12, 2026 · NCT05292664

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

  • Emory University - WINSHIP Cancer Center, Atlanta
  • Emory University, Children's Healthcare of Atlanta, Atlanta
Ap rekriteFaz 1
Laj 12 ak plis · Tout sèks · Mizajou Jan 8, 2026 · NCT04872478

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Healthcare of Atlanta, Emory University, Atlanta
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.